# A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases.

3	Hari Krishnan Krishnamurthy <sup>1</sup> *, Vasanth Jayaraman <sup>1</sup> , Karthik Krishna <sup>1</sup> , Tianhao Wang <sup>1</sup> ,
4	Kang Bei <sup>1</sup> , Chithra Suresh <sup>2</sup> , Shiny Matilda <sup>2</sup> , Alex J Rai <sup>3</sup> , Renata Welc-Falęciak <sup>4</sup> , Agnieszka
5	Pawełczyk <sup>5</sup> , Lucas S. Blanton <sup>6</sup> , Aleš Chrdle <sup>7</sup> , Andrea Fořtová <sup>8</sup> , Daniel Růžek <sup>9</sup> , Gheyath K.
6	Nasrallah <sup>10</sup> , Laith J. Abu-Raddadi <sup>10</sup> , Duaa W. Al-Sadeq <sup>10</sup> , Marah Abed Alhakim Abdallah <sup>10</sup> ,
7	Daniele Lilleri <sup>11</sup> , Chiara Fornara <sup>11</sup> , Piera D'Angelo <sup>11</sup> , Milena Furione <sup>11</sup> , Maria Söderlund-
8	Venermo <sup>12</sup> , Klaus Hedman <sup>12</sup> , Dimosthenis Chochlakis <sup>13</sup> , Anna Psaroulaki <sup>13</sup> , Eirini
9	Makridaki <sup>13</sup> , Artemis Ntoula <sup>13</sup> , John J. Rajasekaran <sup>1</sup> .
10	
11	1 Vibrant Sciences LLC., San Carlos, CA, United States of America
12	2 Vibrant America LLC., San Carlos, CA, United States of America
13	3 Columbia University, Irving Medical Center, Dept. of Pathology & Cell Biology
14	4 Department of Parasitology, Faculty of Biology, University of Warsaw, Diagnostic
15	Laboratory of Parasitic Diseases and Zoonotic Infections, Biological and Chemical Research

- 16 Centre, Warsaw, Poland.
- 17 5 Department of Immunopathology of Infectious and Parasitic Diseases, Medical University
- 18 of Warsaw, 3C Pawińskiego Street, 02-106, Warsaw, Poland
- 19 6 Department of Internal Medicine, Division of Infectious Diseases, University of Texas
- 20 Medical Branch, Galveston, TX 77555, USA.
- 21 7 Department of Infectious Diseases, Hospital Ceske Budejovice, Ceske Budejovice, Czech
- 22 Republic; Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, UK.
- 23 8 Veterinary Research Institute, Brno, Czech Republic; Faculty of Science, Masaryk
- 24 University, Brno, Czech Republic

- 25 9 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske
- 26 Budejovice, Czech Republic; Veterinary Research Institute, Brno, Czech Republic, Faculty of
- 27 Science, Masaryk University, Brno, Czech Republic.
- 28 10 Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha
- 29 P.O. Box 2713, Qatar.
- 30 11 Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- 12 Virology, University of Helsinki, Haartmaninkatu 3, FI-00290, Helsinki, Finland.
- 32 13 Laboratory of Clinical Microbiology and Microbial Pathogenesis, School of Medicine,
- 33 University of Crete, PC 70013, Heraklion Crete Greece.
- 34
- 35 Corresponding Author: \* hari@vibrantsci.com (HKK)
- 36 Vasanth Jayaraman: vasanth.jayaraman@vibrantsci.com
- 37 Karthik Krishna: karthik@vibrantsci.com
- 38 Tianhao Wang: tianhao.wang@vibrantsci.com
- 39 Kang Bei: kang@vibrantsci.com
- 40 Chithra Suresh: chithra.s@vitasoft-tech.com
- 41 Shiny Matilda: shiny.m@vitasoft-tech.com
- 42 Alex J Rai: ajr2170@cumc.columbia.edu
- 43 Renata Welc-Falęciak: rwelc@biol.uw.edu.pl
- 44 Agnieszka Pawełczyk: agnieszka.pawelczyk@wum.edu.pl
- 45 Lucas Blanton: lsblanto@utmb.edu
- 46 Aleš Chrdle: chrdle.ales@nemcb.cz
- 47 Andrea Fořtová: fortova@vri.cz
- 48 Daniel Růžek: ruzekd@paru.cas.cz
- 49 Gheyath K. Nasrallah: gheyath.nasarallah@qu.edu.qa

- 50 Laith J. Abu-Raddadi: lja2002@qatar-med.cornell.edu
- 51 Duaa W. Al-Sadeq: da1206066@student.qu.edu.qa
- 52 Marah Abed Alhakim Abdallah: marah.hakim3@gmail.com
- 53 Daniele Lilleri: d.lilleri@smatteo.pv.it
- 54 Chiara Fornara: c.fornara@smatteo.pv.it
- 55 Piera D'Angelo: p.dangelo@smatteo.pv.it
- 56 Milena Furione: m.furione@smatteo.pv.it
- 57 Maria Söderlund-Venermo: maria.soderlund-venermo@helsinki.fi
- 58 Klaus Hedman: klaus.hedman@helsinki.fi
- 59 Dimosthenis Chochlakis: surreydimos@hotmail.com
- 60 Anna Psaroulaki: psaroulaki@uoc.gr
- 61 Eirini Makridaki: rmakridaki@yahoo.gr
- 62 Artemis Ntoula: artemisntoula@gmail.com
- 63 John J. Rajasekaran: jjrajasekaran@vibrantsci.com
- 64

65 66

67

- 68
- 69
- 70 71
- \_\_\_\_\_

72

- 73
- 74

#### 75 Abstract

76 Tick-borne infections are the most common vector-borne diseases in the USA. Ticks harbor 77 and spread several infections with Lyme disease being the most common tickborne infection 78 in the US and Europe. Lack of awareness about tick populations, specific diagnostic tests, 79 and overlapping symptoms of tick-borne infections can often lead to misdiagnosis affecting 80 treatment and the prevalence data reported especially for non-Lyme tick-borne infections. 81 The diagnostic tests currently available for tick-borne diseases are severely limited in their 82 ability to provide accurate results and cannot detect multiple pathogens in a single run. The 83 multiplex protein microarray developed at Vibrant was designed to detect multiple 84 serological antibodies thereby detecting exposure to multiple pathogens simultaneously. Our 85 microarray in its present form can accommodate 400 antigens and can multiplex across 86 antigen types, whole cell sonicates, recombinant proteins, and peptides. A designed array 87 containing multiple antigens of several microbes including Borrelia burgdorferi, the Lyme 88 disease spirochete, was manufactured and evaluated. The immunoglobulin M (IgM) and G 89 (IgG) responses against several tick-borne microbes and other infectious agents were 90 analyzed for analytical and clinical performance. The microarray improved IgM and IgG 91 sensitivities and specificities of individual microbes when compared with the respective gold 92 standards. The testing was also performed in a single run in comparison to multiple runs 93 needed for comparable testing standards. In summary, our study presents a flexible multiplex 94 microarray platform that can provide quick results with high sensitivity and specificity for 95 evaluating exposure to varied infectious agents especially tick-borne infections.

96 Keywords: Tick-borne infections, Lyme disease, multiplex, microarray, immunoglobulin,
97 tick bite, co-infections, infectious disease.

98

99

#### 100 Introduction

101 Most vector-borne infections in the USA can be attributed to pathogens transmitted via tick 102 bites. Of all tick-borne infections identified to date, Lyme disease is the most prevalent 103 infection [1]. Lyme disease is a potentially serious bacterial infection transmitted by ticks and 104 was first reported in the mid-1970s in the USA. The etiological agent was identified later as 105 Borrelia burgdorferi [2,3,4]. Several studies have reported the presence of co-infections 106 along with Lyme disease [5] including Babesia spp. [6], Bartonella spp. [7], Ehrlichia spp. 107 [8], Anaplasma phagocytophilum [8], Powassan Virus [9], Toxoplasma gondii [10], Rickettsia spp. [11], tick-borne encephalitis virus [12], and West Nile virus [13]. 108 109 Additionally, prolonged exposure to Lyme and other tick-borne infections could potentially 110 weaken the patient's immune system increasing the risk of infections like Epstein Barr virus 111 [14], cytomegalovirus [14], parvovirus B19 [5], coxsackie virus [15], HSV-1 [16], HSV-2 112 [16], and HHV-6 [14].

113

114 Ticks have been shown to transmit more than one infectious agent in a single bite. For 115 instance, a study by Wormser et al. showed that there was a chance of getting infected with A. 116 phagocytophilum (30%) and B. microti (24%) along with Lyme disease [17]. Currently, 117 multi-tiered testing is carried out for diagnosing tick-borne infections [18] 118 (https://tinyurl.com/yeyxevve). In this method, the infectious agents are tested sequentially, 119 starting with Lyme disease. This method is time-consuming and can often lead to delayed 120 diagnosis, accompanied with high cost to the patient [18, 19] (<u>https://tinyurl.com/yeyxevve</u>). 121 Testing for multiple infections in a single run can help physicians arrive at an accurate 122 diagnosis especially since Lyme disease shares symptoms with other vector-borne co-123 infections [20]. The existing diagnostic assays possess various limitations that restrict their 124 applicability in the diagnosis of these infections. The diagnosis of Lyme disease and other

125 infections using several blot-based and single-plex ELISA tests remain rudimentary in terms 126 of arriving at a diagnostic conclusion [21]. Additionally, blot-based assays may have 127 overlapping proteins with similar mass requiring additional testing to tease out the specific 128 antigen to which the antibody is bound. A multiplex system can detect the biomarkers of 129 Lyme disease, potential co-infections, and other infections in a single run. A serology-based 130 multiplexing system may be preferred to a PCR multiplex system mainly due to its 131 accessibility, for instance using dried blood spots [22]. Additionally, serology overcomes the 132 issue of low availability of genetic material due to the transient nature of some of these 133 organisms [23]. A serological-based system is also ideal for population screening and 134 surveillance since it can indicate past exposure to a pathogen.

135

136 Our customisable protein microarray design includes antigens physically separated by design 137 unlike blot assays and can multiplex across species. Multiplexing can also be done across 138 antigen types such as recombinant proteins, peptides, and lysates simultaneously. This 139 method can lower test costs since all the manufacturing is automated using bio customised 140 semiconductor processes similar to how electronic chips are made. The multiplex microarray 141 has three main advantages over the existing technologies. It has an ultra-high-density array 142 surface with high reproducibility and better throughput. It can detect a large number of 143 antibodies against varied infectious agents at the same time. Detection of antibodies can be 144 performed using low sample volumes with low cost and a fast turnaround time [21]. Given 145 the flexible nature of the multiplex platform, we aimed to provide a multiplexed testing 146 solution for Lyme, its co-infections, and other possible infections of interest.

147

148 Materials and Methods

149 Patients Sera

150 The sera from 2990 individuals were collected after seeking appropriate Institutional Review 151 Board (IRB) approval under respective collaborators (Supplementary Table 6). Table 1 lists 152 the provided samples for Lyme disease, co-infections, and other infections along with the 153 counts, respective collaborators and methods used to ascertain the clinical diagnosis by the 154 physician. These reference sera were tested at Vibrant America Clinical Labs (CLIA and 155 CAP accredited facility) by laboratory personnel in a blinded manner. The sera from healthy 156 patients were considered negative and were used to set the cut-off values and were 157 investigated under IRB exemption (work order #1-1574995-1) determined by the Western 158 Institutional Review Board (WIRB) to employ de-linked and de-identified human specimens 159 and medical data for research findings. The negative sera were collected from across the US 160 including endemic and nonendemic regions for these infections.

161

#### 162 **Processing of Wafers**

163 Wafers were functionalized as described previously [21,24] (https://tinyurl.com/mr9ctppy). 164 Briefly, silicon wafers were exposed to an environment of pure oxygen for 2h followed by washing (deionized Water) and coating (1% (vol/vol) with 3-aminopropyltriethoxysilane 165 166 (APTES) in N-methylpyrrolidone (NMP). Curing was carried out at 120 °C for 60 minutes 167 under an N2 atmosphere and humidity-controlled environment. Coating and incubation of the 168 wafer with a co-polymer solution of poly (L-lysine) and poly (lactic acid) for 24h were 169 carried out to increase the binding efficiency of the surface on to which the antigens were 170 immobilized via passive adsorption/hydrophobic interactions with the copolymers [Figure 171 1].

172

#### 173 Immobilization of Antigens

174 The antigens included in the assay are listed in Table 2. Pathogens transmitted by ticks and 175 their respective antigens for potential future additions are listed in Figure 2 [25-30] 176 (https://tinyurl.com/37dprsy7). The recombinant antigens were expressed in E. coli bacteria 177 using full-length cDNA coding for the respective antigens fused with a hexa histidine 178 purification tag. The whole cell sonicate was obtained from organisms cultured according to 179 ATCC protocols prior to lysing them which yielded a cocktail of the cell membrane, cell 180 wall, and cytosolic proteins. Peptide antigens were synthesized by photolithography as shown 181 in our previous publications [31,32]. The capture antigens including the recombinant antigens 182 that mimic the natural pathogen and the whole-cell sonicate were incubated on the wafer at a 183 concentration of 1.0 µg/ml and reacted for 24h at 4 °C. The unbound antigens were removed 184 by washing with aqueous phosphate buffer and the unreacted substrate was quenched with a 185 blocking solution containing BSA and glycine. The immobilized antigens were classified 186 with unique identifiers assigned to each wafer. In this study, we employed the microarray to 187 detect Lyme disease, co-infections, and other agents of interest including, B. microti, B. 188 henselae, A. phagocytophilum, E. chaffeensis, R. typhi, Powassan virus, tick-borne 189 encephalitis virus, West Nile virus, coxsackie virus, cytomegalovirus, Epstein Barr virus, 190 parvovirus B19, T. gondii, HSV-1, HSV-2, and HHV-6 [Figure 2].

191

#### 192 Pillar Plate Assembly

Individual wafers were stealth diced into 0.70 x 0.70mm<sup>2</sup> microchips for each antigen. A standard die-sorting system was used to pick and place these wafers onto individual carrier tapes. The carrier tapes were then placed onto a high-throughput surface mount technology (SMT) component placement system. Finally, microchips were mounted onto 24 pillar plates and each pillar contains 87 microchips with each chip designated for one antigen – recombinant protein, peptide or whole cell sonicates [Figure 1].

199

#### 200 Immunochip assay and Antibody detection

201 Serum samples were probed using 1:20 dilution on the pillar plate and incubated for 1h at 202 room temperature followed by alternate washing and incubation as described previously [21]. 203 The plate was then incubated for an hour with the secondary antibody (1:2000 dilution of 204 Goat Anti-Human IgG HRP and Goat Anti-Human IgM HRP individually) and washed with 205 TBST buffer followed by DI Water. The plates were left for drying preceding the addition of 206 chemiluminescent substrate and the performance of chemiluminescent imaging. An enhanced 207 IgM sensitivity was achieved by pre-reacting the sera with proprietary assay components 208 leading to IgG stripping prior to IgM testing.

209

210 The detection of multiplex antibodies is based on the chemiluminescent immunoassay and 211 can be performed using  $<200 \,\mu$ L of serum. Sample dilution, multi-step incubation, and multi-212 solution washing are programmed into liquid handlers. The immunochip has the capacity to 213 assay 192 individual specimens in 2h. Raw chemiluminescent signals for each probe are 214 extracted and converted into intensity plots by an in-house reporter software. This method of 215 automatic antigen detection can dramatically shorten the turnaround time, reduce the cost of 216 labor and instrument, and eliminate the need for manual handling and subjective 217 interpretation of the WB or IB test results when compared to the traditional two-tiered testing 218 recommended by the CDC. All the antibodies are detected in a single run.

219

#### 220 Data analysis

An in-house software extracts the chemiluminescent signals from the generated images which were converted to intensity plots. The average intensity of each antibody was compared with the cut-off values assigned for each antigen to track seropositivity.

224

### 225 **Results**

#### 226 Custom Protein Microarray Platform

227 The main components of the Immunochip platform include multiple silicon-based 0.70 imes228  $0.70 \text{ mm}^2$  microchips that are laser diced from antigen-immobilized wafers, a customized 24 229 well compatible plate containing 24 pillars, each containing 87 microchips that are picked 230 and placed into a multiplex microarray assembly, and a high-resolution imager capable of 231 simultaneously detecting chemiluminescent signals from labelled antigen-antibody reactions 232 at each microchip throughout the multiplex microarray (Figure 1). Each chip can be 233 considered analogous to an individual band in a Western blot; however, the proteins are 234 physically separated eliminating cross-reactive issues usually seen in blot-based assays for 235 proteins with similar mass. Figure 1 provides an overview of the microarray manufacturing 236 process. Figure 2 shows the individual chips that are placed in each pillar, a single serum 237 sample will be applied to each pillar thereby assaying the antibodies in serum against all 238 antigens at the same time.

239

#### 240 Analysis of serological response

The Vibrant tick-borne disease panel tests for IgG and IgM antibodies for Lyme disease and other infectious agents as mentioned in Table 2 and Figure 2. The IgM and IgG immune responses were analysed, and the clinical sensitivities and specificities were tabulated in Table 3. The samples reacted with a specific immunoreactive epitope of the 87 different antigens that were being tested. The immunoreactivity of these antigens was contrasted with that of the controls.

247

#### 248 Enhanced IgM Assay

IgM antibodies are the primary antibodies produced by the immune system during infections, but they make up only 5% to 10% of all the circulating antibodies [33]. An in-house IgM assay was developed to remove most IgG antibodies and other non-specific proteins from the serum prior to the IgM immunoassay. This helped to increase the sensitivity and specificity of the assay. Human IgG was removed by incubating the serum with a purified goat antihuman (GAH) IgG Fc fragment and proprietary assay reagents.

255

#### 256 Analytical Performance

257 analytical performance of the immunochip was evaluated for precision The 258 (repeatability/reproducibility), analytical sensitivity, reportable range, linearity, and matrix 259 equivalency studies. Samples for negatives, low or moderate positives, and high positives 260 were run with duplication to determine the analytical performance metrics. The precision 261 study used a panel of 11 samples and was run over a period of 20 days with 2 duplicates per 262 run and 4 runs per day. The results are tabulated as shown in Supplementary Table 1. Lot to 263 Lot reproducibility was also tested to check for variation in the manufacturing of the pillar 264 plates by running a panel of 11 samples with 5 replicates per run, 3 runs per day over a period 265 of 5 days using 3 manufactured lots. The results are tabulated as shown in Supplementary 266 Table 2. Testing of protein-free serum matrix samples and low antibody concentration 267 samples with 2 replicates per run, 2 runs per day over a period of three days was used to 268 determine analytical sensitivity. The limit of blank (LoB) and limit of quantitation (LoQ) was 269 calculated using the mean and standard deviation of the blank and the low antibody 270 concentration samples as shown in Supplementary Table 3. The linearity and reportable range 271 were verified by running samples with varying levels of antibodies and checking assay

recovery, the results are tabulated in Supplementary Table 4. Matrix equivalence studies are shown in Supplementary Table 5. The potential interference of specific endogenous and exogenous substances with the immunochip was evaluated by performing an interfering substance study. The interfering substances tested were 60 mg/dl bilirubin, 100 mg/ml cholesterol, 1000 mg/ml triglycerides, 1000 mg/ml hemoglobin, and 6 g/dl albumin. There was no interference between the immunochip and the substances tested at the mentioned levels.

279

#### 280 Clinical Sensitivity and Specificity

Table 3 provides an overview of the IgG and IgM sensitivities measured by the Vibrant microarray. This is compared with the sensitivities and specificities of the current gold standard tests for the particular pathogen. The Vibrant microarray was able to achieve high sensitivities and specificities when compared with the gold standards for each pathogen. Supplementary Table 7 provides more details on the gold standard diagnostic tests for the pathogens along with the modes of transmission and their endemic regions.

287

### 288 Evaluating the antigens of *Borrelia burgdorferi*

289 In this study, individual antigens of *B. burgdorferi* were tested for reactivity with IgG and 290 IgM antibodies (Table 4). The heat map (Figure 3) shows the performance metrics of the 291 different antigens. Testing for Lyme disease since 1994 has been based on conventional two-292 tiered testing (CTTT) where an enzyme immunoassay (EIA) is followed by a specific 293 immunoblot for a definitive diagnosis. Recently, CTTT has been replaced with a modified 294 two-tier testing (MTTT) in which an EIA using whole cell sonicate is followed by an EIA 295 using C6 peptide. This shows the increasing shift away from blot-based testing to 296 conventional ELISA. MTTT removes the burden of immunoblots which are tedious to run,

297 more expensive and could have subjective interpretation of bands [49]. Complete 298 replacement of immunoblots can be done using a microarray platform such as the one 299 described here. The full data set would be available to the physicians to make a nuanced 300 diagnosis instead of a narrow subset of antigens run on ELISAs.

301

### 302 Discussion

303 Ticks are among the most important sources of vector-borne infections in the US [50]. The 304 spread of ticks across the US has been steadily increasing over the past decades. In parallel, 305 the discovery of novel pathogens that are spread by ticks has also seen dramatic increases 306 [51]. Currently, there are 11 major tickborne diseases according to the CDC namely, Lyme 307 disease, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, Southern tick-associated rash 308 illness, tick-borne relapsing fever, tularemia, anaplasmosis, Colorado tick fever, and 309 Powassan encephalitis [52] (https://www.cdc.gov/ticks/diseases/index.html). Patients are 310 rarely tested for all possible infections that could be transmitted via a tick bite [53]. The 311 current diagnostic tests are severely limited in distinguishing various tick-borne infections 312 and several studies have revealed that non-Lyme tick-borne infections are heavily 313 underdiagnosed [54].

314

Among varied testing options PCR and serology-based assays are reliable and most widely used. PCR has several advantages as it detects pathogenic DNA/RNA which conclusively proves the organism's presence. It has high specificity and has a high throughput with assay run times of about 2 hours. It can also detect the infection during its early stages [55]. There are however certain drawbacks to testing using PCR, especially with tickborne infections. Pathogens transmitted by ticks may be transient in the blood resulting in false negative PCR

results in tick-borne diseases, namely, *B. burgdorferi*, *R. typhi*, *T. gondii*, HSV-1, EBV, TBEV, and WNV [23]. PCR testing requires specialised laboratories and equipment for testing. PCR may not detect all strains and variants and is limited to detecting known pathogens [56]. Multiplexing using PCR is limited due to fixed number of analytes that can be parallelly read using PCR instrumentation.

326

327 Serology-based testing has several advantages when it comes to tick-borne infection testing. 328 It has the ability to comprehensively assess immune responses and simultaneously detect 329 exposure to multiple pathogens including previous and unresolved infections. Testing two 330 times with a time interval in between can also help diagnose active infections based on 331 altered serum antibody profiles. Simultaneous detection of antibodies against multiple tick-332 borne pathogens using a single sample and providing a comprehensive view of the patient's 333 immune response is a key advantage of serology-based multiplex testing [23]. The testing can 334 also be done in resource poor settings with collection using a dried blood spot [22]. 335 Serological testing can diagnose tick-borne diseases even in the later stages when pathogen 336 detection through molecular methods becomes more challenging [23,57]. It also reduces the 337 risk of false negatives [57]. Serological multiplex testing being cost-effective can also 338 contribute to surveillance and epidemiological studies by providing valuable data on the 339 prevalence and distribution of tick-borne diseases, enhancing our understanding of disease 340 dynamics [58]. However, serological studies have their own limitations. Serological testing 341 may not be able to detect early/recent infections. It relies heavily on the timing of sample 342 collection and the host's immune responses. In certain cases, molecular testing may be needed 343 to confirm serological testing [23]. Despite all this, the benefits of serology testing outweigh 344 its limitations which is why it is recommended by the CDC as the standard of testing for 345 Lyme disease.

346

Apart from PCR and ELISA serology tests, IFA and culture methods have also been suggested for diagnosing tick-borne infections. Testing using IFA is limited due to a lack of standardized antigenic targets, the subjective establishment of positive thresholds, and cross reactivity. These factors can result in varying accuracy of IFA results across laboratories [23]. Furthermore, Bacterial or viral cultures are not recommended for the diagnosis of tick-borne infections. This is due to the time-consuming nature of the test, the need for special media, and procedures that are only performed at specific laboratories [61].

354

355 This study employed a serology-based microarray developed at Vibrant to multiplex Lyme 356 and other tick-borne infections along with a few other infections of interest. The uniqueness 357 of the microarray lies in the application of the immunodominant antigens that eliminate 358 nonspecific binding with high sensitivity needed for accurate diagnosis. Antigens could be 359 evaluated in a multiplex setting to gauge their performance with clinical samples to pick the 360 ideal set of antigens for any infection. To the best of our knowledge, this is the first report on 361 the broad panel of antigens for Lyme disease and its co-infection testing in such a flexible 362 format. The structure of the Vibrant pillar plate is designed to encompass 400 probe chips at 363 each pillar facilitating the detection of an array of co-infections in a single run, saving cost, 364 labor, and time. Further compaction of the chip allows improved performance by enhancing 365 multiplexing and widening its clinical applications. The microarray platform is advantageous 366 over other existing gold standards for tick-borne diseases and was able to overcome several 367 of their limitations. Average time for multitier testing for several tickborne pathogens could 368 take several months whereas the microarray technology takes only about a day to perform 369 [21]. The microarray detected 17 tick-borne and other infections along with Lyme disease 370 with sensitivities and specificities listed in Table 3.

371

372 In conclusion, the protein microarray with a multiplex of antigens was validated for Lyme 373 and its co-infections. The impact of simultaneous testing of co-infections leads to focused and 374 efficacious therapeutic recommendations. This approach caters to the diagnostic needs of 375 patients owing to its high sensitivity and specificity, affordable cost, quick availability of 376 results, and low sample volume requirement. Measures for syndromic surveillance, 377 diagnostic preparedness in disease outbreak investigations, personal protection, and education 378 of clinical health professionals and patients could pave the way for controlling tick-borne 379 infections better. As the known repertoire of antigens increases, this flexible microarray 380 format can be customised to include these new antigens. Future editions could also include 381 other infections/agents namely Colorado tick fever, heartland virus, rickettsiosis, Rocky 382 Mountain spotted fever, Southern tick-associated rash illness, tick-borne relapsing fever, and 383 tularemia which can be tested in parallel. Novel antigens for pathogens which may include 384 whole cell sonicates, recombinant proteins or peptide epitopes can be added as the science 385 progresses leading to continuous improvement in diagnostic technology for detecting tick-386 borne infections.

387

388 Declarations:

389 Author Contributions

Conception and study design: HKK, JJR, VJ. Performing experiments: KK, TW. Analysis
and interpretation: KB, KK. Writing-original draft: HKK, CS, SM. Review and editing:
HKK, CS, AJR, RWF, AP, LSB, AC, AF, DR, GKN, LJA, DWA, MAA, DL, CF, PD, MF,
MSV, KH, DC, AP, EM, and AN. Sample resources: RWF, AP, LSB, AC, AF, DR, GKN,
LJA, DWA, MAA, DL, CF, PD, MF, MSV, KH, DC, AP, EM, and AN. All authors

reviewed and approved the final manuscript.

#### 396 Competing interests

397	The authors have read the journal's policy and the authors of this manuscript have the
398	following competing interests: CS and SM are paid employees of Vibrant America LLC. KK,
399	VJ, TW, KB, HKK, and JJR are paid employees of Vibrant Sciences LLC. The other authors
400	are academic collaborators who provided samples and assisted in the review and editing of
401	the manuscript. AJR is a paid consultant of Vibrant America LLC. Vibrant America offers
402	commercial testing for Lyme disease and other infectious diseases and could benefit from
403	increased testing.
404	Funding
405	Vibrant America provided funding for this study in the form of salaries for authors [CS, SM,
406	KK, VJ, TW, KB, HKK, JJR]. The funders had no role in study design, data collection,

407 analysis, decision to publish, or preparation of the manuscript.

408 Acknowledgment

409 Vibrant Sciences LLC developed the microarray technology showcased in the publication.

410 All IP associated with the microarray manufacture and diagnostics belongs to Vibrant

411 Sciences. The specific roles of authors are stated in the author contribution section.

- 412 Availability of Data
- 413 The data used to support the findings of this study can be acquired from Vibrant America

414 LLC.

415 References

Rochlin, I., & Toledo, A. (2020). Emerging tick-borne pathogens of public health
importance: a mini-review. *J Med Microbiol*, 69(6), 781–791.

418	2.	Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E., & Davis,
419		J. P. (1982). Lyme disease—a tick-borne spirochetosis?. Science, 216(4552), 1317-
420		1319.
421	3.	Johnson, R. C., Schmid, G. P., Hyde, F. W., Steigerwalt, A. G., & Brenner, D. J.
422		(1984). Borrelia burgdorferi sp. nov.: etiologic agent of Lyme disease. International
423		Journal of Systematic and Evolutionary Microbiology, 34(4), 496-497.
424	4.	Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W., &
425		Mead, P. S. (2016). Lyme borreliosis. <i>Nature reviews Disease primers</i> , 2(1), 1-19.
426	5.	Berghoff, W. (2012). Chronic Lyme Disease and Co-infections: Differential
427		Diagnosis. Open Neurol J, 6(Suppl 1), 158–178.
428	6.	Knapp, K. L., & Rice, N. A. (2015). Human Coinfection with Borrelia burgdorferi
429		and Babesia microti in the United States. J Parasitol Res, 16(3), 385-391.
430	7.	Angelakis, E., Billeter, S. A., Breitschwerdt, E. B., Chomel, B. B., & Raoult, D.
431		(2010). Potential for Tick-borne Bartonelloses. Emerg Infect Dis, 16(3), 385–391.
432	8.	Ismail, N., Bloch, K. C., & McBride, J. W. (2010). Human Ehrlichiosis and
433		Anaplasmosis. Clin Lab Med, 30(1), 261–292.
434	9.	Hart, C. E., Middleton, F. A., & Thangamani, S. (2022). Infection with Borrelia
435		burgdorferi Increases the Replication and Dissemination of Coinfecting Powassan
436		Virus in Ixodes scapularis Ticks. Viruses, 14(7), 1584.
437	10	Ben-Harari, R. R. (2019). Tick transmission of toxoplasmosis. Expert Review of Anti-
438		<i>infective Therapy</i> , <i>17</i> (11), 911-917.
439	11.	Koetsveld, J., Tijsse-Klasen, E., Herremans, T., Hovius, J. W. R., & Sprong, H.
440		(2016). Serological and molecular evidence for spotted fever group Rickettsia and
441		Borrelia burgdorferi sensu lato co-infections in The Netherlands. Ticks Tick Borne
442		Dis, 7(2), 371-7.
443	12	Gustafson, R., Svenungsson, B., Gardulf, A., Stiernstedt, G., & Forsgren, M. (1990).
444		Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish
445		population. Scand J Infect Dis, 22(3), 297-306.
446	13.	Lawrie, C. H., Uzcátegui, N. Y., Gould, E. A., & Nuttall, P. A. (2004). Ixodid and
447		argasid tick species and West Nile virus.
448	14.	Smith, A., Oertle, J., Warren, D., & Prato, D. (2015). Chronic Lyme Disease Complex
449		and Its Commonly Undiagnosed Primary and Secondary Co-Infections. Open Journal
450		of Medical Microbiology, 5(3).
451	15.	Freundt, E. C., Beatty, D. C., Stegall-Faulk, T., & Wright, S. M. (2005). Possible
452		Tick-Borne Human Enterovirus Resulting in Aseptic Meningitis. J Clin Microbiol,
453		43(7), 3471–3473.
454	16	Gylfe, A., Wahlgren, M., Fahlén, L., & Bergström, S. (2002). Activation of latent
455		Lyme borreliosis concurrent with a herpes simplex virus type 1 infection. Scand J
456		Infect Dis. 34(12), 922-4.
457	17	Wormser, G. P., McKenna, D., Scavarda, C., Cooper, D., El Khoury, M. Y.,
458		Nowakowski, J., & Wong, S. J. (2019). Co-infections in persons with early Lyme
459		disease. New York, USA. Emerging infectious diseases 25(4) 748
460	18	Quest diagnostics. (2018). Tick-borne Diseases Quest Diagnostics
461	19	Drew, D., & Hewitt, H. (2006). A qualitative approach to understanding natients'
462	- / 1	diagnosis of Lyme disease. <i>Public Health Nursing</i> . 23(1), 20-26.
		······································

463	20	. Beck, S., Nakajima, R., Jasinskas, A., Abram, T. J., Kim, S. J., Bigdeli, N., &
464		Zhao, W. (2022). A protein microarray-based respiratory viral antigen testing
465		platform for COVID-19 surveillance. <i>Biomedicines</i> , 10(9), 2238.
466	21	Jayaraman, V., Krishna, K., Yang, Y., Rajasekaran, K. J., Ou, Y., Wang, T., Bei, K.,
467		Krishnamurthy, H. K., Rajasekaran, J. J., Rai, A. J., & Green, D. A. (2020). An ultra-
468		high-density protein microarray for high throughput single-tier serological detection
469		of Lyme disease. Scientific Reports, 10, 18085.
470	22	Grossberg, A. N., Koza, L. A., Ledreux, A., Prusmack, C., Krishnamurthy, H. K.,
471		Jayaraman, V., Granholm, A. C., & Linseman, D. A. (2021). A multiplex
472		chemiluminescent immunoassay for serological profiling of COVID-19-positive
473		symptomatic and asymptomatic patients. <i>Nature communications</i> , 12(740).
474	23	Tokarz, R., Mishra, N., Tagliafierro, T., Sameroff, S., Caciula, A., Chauhan, L., Patel,
475		J., Sullivan, E., Gucwa, A., Fallon, B., Golightly, M., Molins, C., Schriefer, M.,
476		Marques, A., Briese, T., & Lipkin, W. I. (2018). A multiplex serologic platform for
477		diagnosis of tick-borne diseases. Sci Rep, 8(3158).
478	24.	Rajasekaran, J. J., Javaraman, V., Wang, T., Bei, K., Krishnamurthy, H, K. (2016).
479		Methods, systems, and arrays for biomolecular analysis. Patent No. 9417236B2.
480		United States.
481	25.	Centers for Disease Control and Prevention. (2022, August 5). Tickborne Diseases of
482		the United States. Centers for Disease Control and Prevention. Retrieved September
483		8, 2023.
484	26	Alhassan, A., Liu, H., McGill, J., Cerezo, A., Jakkula, L. U. M. R., Nair, A. D. S.,
485		Winkley, E., Olson, S., Marlow, D., Sahni, A., Narra, H. P., Sahni, S., Henningson, J.,
486		& Ganta, R. R. (2019). Rickettsia rickettsii Whole-Cell Antigens Offer Protection
487		against Rocky Mountain Spotted Fever in the Canine Host. Infection and immunity,
488		87(2), e00628-18.
489	27	Blanc, G., Ngwamidiba, M., Ogata, H., Fournier, P. E., Claverie, J. M., & Raoult, D.
490		(2005). Molecular evolution of rickettsia surface antigens: evidence of positive
491		selection. Molecular biology and evolution, 22(10), 2073-2083.
492	28	Pornwiroon, W., Bourchookarn, A., Paddock, C. D., & Macaluso, K. R. (2009).
493		Proteomic analysis of Rickettsia parkeri strain portsmouth. Infection and immunity,
494		77(12), 5262–5271.
495	29	. Kubelkova, K., & Macela, A. (2021). Francisella and Antibodies. Microorganisms,
496		9(10), 2136.
497	30	. Zhu, Y., Wu, Y., Chai, Y., Qi, J., Peng, R., Feng, W. H., & Gao, G. F. (2017). The
498		Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic
499		Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae. Journal of
500		virology, 92(1), e01558-17.
501	31	Marietta, E. V., Choung, R. S., Van Dyke, C. T., Brantner, T. L., Rajasekaran, J. J.,
502		Pasricha, P. J., Wang, T., Bei, K., Krishna, K., Krishnamurthy, H. K., Snyder, M. R.,
503		Jayaraman, V., & Murray, J. A. (2016). Determination of B-Cell Epitopes in Patients
504		with Celiac Disease: Peptide Microarrays. PLoS One, 11(1), e0147777.
505	32	Rostamkolaei, S. K., Choung, R. S., Ju, J. M., Marietta, E. V., Van Dyke, C. T.,
506		Rajasekaran, J. J., Jayaraman, V., Wang, T., Bei, K., Rajasekaran, K. E., Krishna, K.,
507		Krishnamurthy, H. K., & Murray, J. A. (2019). Synthetic Neoepitopes of the

508 509		Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease. <i>Gastroenterology</i> , 156(3), 582-591.e1.
510	33.	Terry, W. D., & Fahey, J. L. (1964). SUBCLASSES OF HUMAN GAMMA-2-
511		GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE
512		CHAINS. Science, 146(3642), 400-1.
513	34.	Moore, A., Nelson, C., Molins, C., Mead, P., & Schriefer, M. (2016). Current
514		guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of
515		Lyme disease, United States. Emerging infectious diseases, 22(7), 1169.
516	35.	Ortiz, J. F., Millhouse, P. W., Cox, A. M., Campoverde, L., Kaur, A., Wirth, M., &
517		Atoot, A. (2020). Babesiosis: appreciating the pathophysiology and diverse sequela of
518		the infection. Cureus, 12(10).
519	36.	Allizond, V., Costa, C., Sidoti, F., Scutera, S., Bianco, G., Sparti, R., & Musso, T.
520		(2019). Serological and molecular detection of Bartonella henselae in specimens from
521		patients with suspected cat scratch disease in Italy: A comparative study. PloS one,
522		<i>14</i> (2), e0211945.
523	37.	Reller, M. E., & Dumler, J. S. (2018). Development and clinical validation of a
524		multiplex real-time quantitative PCR assay for human infection by Anaplasma
525		phagocytophilum and Ehrlichia chaffeensis. Tropical medicine and infectious disease,
526		3(1), 14.
527	38.	Stewart, A. G., & Stewart, A. G. (2021). An update on the laboratory diagnosis of
528		Rickettsia spp. infection. Pathogens, 10(10), 1319.
529	39.	Thomm, A. M., Schotthoefer, A. M., Dupuis, A. P., Kramer, L. D., Frost, H. M.,
530		Fritsche, T. R., & Kehl, S. C. (2018). Development and validation of a serologic
531		test panel for detection of Powassan virus infection in US patients residing in regions
532		where Lyme disease is endemic. <i>Msphere</i> , 3(1), e00467-17.
533	40.	Reusken, C., Boonstra, M., Rugebregt, S., Scherbeijn, S., Chandler, F., Avšič-Županc,
534		T., & GeurtsvanKessel, C. H. (2019). An evaluation of serological methods to
535		diagnose tick-borne encephalitis from serum and cerebrospinal fluid. Journal of
536		Clinical Virology, 120, 78-83.
537	41.	Sambri, V., Capobianchi, M. R., Cavrini, F., Charrel, R., Donoso-Mantke, O.,
538		Escadafal, C., & Zeller, H. (2013). Diagnosis of west nile virus human infections:
539		overview and proposal of diagnostic protocols considering the results of external
540		quality assessment studies. Viruses, 5(10), 2329-2348.
541	42.	Bryant, P. A., Tingay, D., Dargaville, P. A., Starr, M., & Curtis, N. (2004). Neonatal
542		coxsackie B virus infection-a treatable disease?. European journal of pediatrics,
543		163, 223-228.
544	43.	A Ross, S., Novak, Z., Pati, S., & B Boppana, S. (2011). Overview of the diagnosis of
545		cytomegalovirus infection. Infectious Disorders-Drug Targets (Formerly Current
546		Drug Targets-Infectious Disorders), 11(5), 466-474.
547	44.	Jenson, H. B. (2004). Virologic diagnosis, viral monitoring, and treatment of Epstein-
548		Barr virus infectious mononucleosis. Current Infectious Disease Reports, 6, 200-207.
549	45.	Manaresi, E., Gallinella, G., Zuffi, E., Bonvicini, F., Zerbini, M., & Musiani, M.
550		(2002). Diagnosis and quantitative evaluation of parvovirus B19 infections by
551		real time PCR in the clinical laboratory. Journal of medical virology, 67(2), 275-
552		281.

553	46	Souza, I. M. F. N. B. D., Siqueira, V. D. S., Ribeiro, I. D. C., Moraes, L. S. P., Prado,
554		D. P. G. D., Rezende, S. R., & Rezende, H. H. A. (2023). Molecular and
555		serological diagnosis of toxoplasmosis: a systematic review and meta-analysis.
556		Revista do Instituto de Medicina Tropical de São Paulo, 65, e19.
557	47.	Singh, A., Preiksaitis, J., & Romanowski, B. (2005). The laboratory diagnosis of
558		herpes simplex virus infections. Canadian Journal of Infectious Diseases and Medical
559		Microbiology, 16(2), 92-98.
560	48.	Norton, R. A., Caserta, M. T., Hall, C. B., Schnabel, K., Hocknell, P., & Dewhurst, S.
561		(1999). Detection of human herpesvirus 6 by reverse transcription-PCR. Journal of
562		clinical microbiology, 37(11), 3672-3675.
563	49.	Lipsett, S. C., Branda, J. A., & Nigrovica, L. E. (2019). Evaluation of the Modified
564		Two-Tiered Testing Method for Diagnosis of Lyme Disease in Children. J Clin
565		Microbiol, 57(10), e00547-19.
566	50.	Eisen, R. J., Kugeler, K. J., Eisen, L., Beard, C. B., & Paddock, C. D. (2017). Tick-
567		Borne Zoonoses in the United States: Persistent and Emerging Threats to Human
568		Health. ILAR J, 58(3), 319–335.
569	51.	Paddock CD, Lane RS, Staples JE, et al. (2016). CHANGING PARADIGMS FOR
570		TICK-BORNE DISEASES IN THE AMERICAS. In: Forum on Microbial Threats;
571		Board on Global Health; Health and Medicine Division; National Academies of
572		Sciences, Engineering, and Medicine. Global Health Impacts of Vector-Borne
573		Diseases: Workshop Summary. Washington (DC): National Academies Press (US).
574	52.	Centers for Disease Control and Prevention. (2022, March 24). Diseases Transmitted
575		by Ticks. Centers for Disease Control and Prevention. Retrieved August 31, 2023.
576	53.	Brown Marusiak, A., Hollingsworth, B. D., Abernathy, H., Alejo, A., Arahirwa, V.,
577		Mansour, O., Giandomenico, D., Schmitz, J., Williams, C., Barbarin, A. M., & Boyce,
578		R. M. (2022). Patterns Testing for Tick-Borne Diseases and Implications for
579		Surveillance in the Southeastern US. JAMA network open, 5(5), e2212334.
580	54.	Institute of Medicine (US) Committee on Lyme Disease and Other Tick-Borne
581		Diseases: The State of the Science. (2011). Diagnostics and Diagnosis. In Critical
582		Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme
583		and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes:
584		Workshop Report. National Academies Press (US).
585	55.	Elnifro, E. M., Ashshi, A. M., Cooper, R. J., & Klapper, P. E. (2000). Multiplex PCR:
586		optimization and application in diagnostic virology. Clin Microbiol Rev, 13(4), 559-
587		70.
588	56.	Liu, H. Y., Hopping, G. C., Vaidyanathan, U., Ronquillo, Y. C., Hoopes, P. C., &
589		Moshirfar, M. (2019). Polymerase chain reaction and its application in the diagnosis
590		of infectious keratitis. Medical Hypothesis, Discovery and Innovation in
591		Ophthalmology, 8(3), 152.
592	57.	Leeflang, M. M., Ang, C. W., Berkhout, J., Biilmer, H. A., Van Bortel, W.,
593		Brandenburg, A. H., Van Burgel, N. D., Van Dam, A. P., Dessau, R. B., Fingerle, V.,
594		Hovius, J. W., Jaulhac, B., Meiier, B., Van Pelt, W., Schellekens, J. F., Spiiker, R.,
595		Stelma, F. F., Stanek, G., Verduvn-Lunel, F., Zeller, H., Sprong, H. (2016). The
596		diagnostic accuracy of serological tests for Lyme borreliosis in Europe <sup>1</sup> a systematic
597		review and meta-analysis. BMC infectious diseases, 16 140

598	58. Hilton, E., DeVoti, J., Benach, J. L., Halluska, M. L., White, D. J., Paxton, H., & Dumlar, J. S. (1999). Scroprovalance and scropenversion for tick horne diseases in a
600	high-risk population in the northeast United States. <i>Am J Med</i> , 106(4), 404-9.
601	59. Centers for Disease Control and Prevention (CDC). (1995). Recommendations for test
602	performance and interpretation from the Second National Conference on Serologic
603	Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep, 44(31), 590-1.
604	60. Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., & Wormser, G. P. (2005).
605	Diagnosis of lyme borreliosis. Clin Microbiol Rev, 18(3), 484-509.
606	61. Theel, E. S., Aguero-Rosenfeld, M. E., Pritt, B., Adem, P. V., & Wormser, G. P.
607	(2019). Limitations and Confusing Aspects of Diagnostic Testing for Neurologic
608	Lyme Disease in the United States. J Clin Microbiol, 57(1), e01406-18.
609	

Pathogen	Ν	Source (scientist/company)	<b>Basis of Diagnosis</b>
Borrelia burgdorferi	298	CDC, Private Clinics	RT-PCR, Physician
Babesia microti	70	Parasitology Laboratory, Wadsworth Center (NYSDOH)	RT-PCR, Blood Smear
Babesia microti	118	Seracare, Boca Bio, Private Clinics	Serology, RT-PCR
Babesia microti	26	Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University)	Physician
Bartonella henselae	119	Private clinics	RT-PCR, Physician
Bartonella henselae	26	Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University)	Physician
Bartonella henselae	10	Dimosthenis Chochlakis (University of Crete)	Physician
Anaplasma phagocytophilum	118	Private clinics, Boca Bio	RT-PCR, Serology
Anaplasma phagocytophilum	26	Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University)	Physician
Ehrlichia chaffeensis	120	Private clinics, Boca Bio	RT-PCR, Serology
Ehrlichia chaffeensis	26	Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University)	Physician
Rickettsia typhi	70	Lucas Blanton (University of Texas Medical Branch)	Physician
Rickettsia typhi	124	Private clinics	RT-PCR, Physician
Powassan virus	127	Private clinics	RT-PCR, Physician
Tick-borne encephalitis	111	Daniel Rużek (Czech Academy of Sciences)	Physician

#### **Table 1 Sample Cohort** 610

Tick-borne encephalitis	124	Private clinics	RT-PCR, Physician
West Nile virus	20	Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar)	Physician
West Nile virus	124	Private clinics	RT-PCR, Physician
Coxsackie virus	45	iSpecimen	Serology
Coxsackie virus	124	Private clinics	RT-PCR, Physician
Cytomegalovirus	43	DLS	Serology
Cytomegalovirus	138	Daniele Lilleri (Fondazione IRCCS Policlinico San Matteo)	Physician
Cytomegalovirus	96	Private Clinics	RT-PCR, Physician
Cytomegalovirus	37	Seracare	Serology
Epstein Barr virus	20	Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar)	Physician
Epstein Barr virus	43	Seracare	Serology
Epstein Barr virus	14	iSpecimen	Serology
Epstein Barr virus	96	Private clinics	RT-PCR, Physician
Parvovirus B19	124	Private clinics	RT-PCR, Physician
Toxoplasma gondii	24	Seracare	Serology
Toxoplasma gondii	124	Private clinics	RT-PCR, Physician
HSV-1	20	Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar)	Physician
HSV-1	31	Seracare	Serology
HSV-1	96	Private clinics	RT-PCR, Physician
HSV-2	19	Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar)	Physician
HSV-2	27	Seracare	Serology
HSV-2	96	Private clinics	RT-PCR, Physician
HHV-6	20	Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar)	Physician
HHV-6	96	Private clinics	RT-PCR, Physician

Table 1 provides an overview of the pathogens used in the study along with the total number

of samples, basis of diagnosis, and sample source.

613

# 614 Table 2 Overview of pathogens and antigens

Pathogen(Tick, if any)	Antigen
B. burgdorferi (I. scapularis)	VlsE1, C6 peptide, DbpB, OspC, p28, p30, OspA, OspB, BmpA, p41, p45, p58, p66, p83-93, WCS B31, WCS 297.

B. mayonii (I. scapularis)	Whole cell sonicate
B. afzelii (I. ricinus, I. persulatus )	BmpA,DbpA,OspA,OspC,p100
B. garinii (I. ricinus, I. persulatus)	DBpA,OspC
B. bavariensis (I. uriae, I. persulcatus)	p58,VLsE1, DbpA
B. spielmanii (I. ricinus)	DBpA,OspC
B. hermsii (O. hermsi)	Whole cell sonicate
B. turicatae (O. turicatae)	Whole cell sonicate
B. miyamotoi (I. dentatus, I. ricinus, I. scapularis, I. pacificus)	GlpQ
B. andersonii (I. dentatus)	Whole cell sonicate
B. maritima (I. spinipalpis)	Whole cell sonicate
B. californiensis (I. jellisonii, I. spinipalpis, I. pacificus)	Whole cell sonicate
B. bissettiae (I.scapularis, I. persulatus, I. spinipalpis, I. pacificus)	Whole cell sonicate
B. lusitaniae (I. Ricinus)	Whole cell sonicate
B. valaisiana (I. ricinus, I. nippopensis, I. columnae)	Whole cell sonicate
B. yangtzensis (I. granulatus, I. nipponensis)	Whole cell sonicate
B. turcica (H. aegypticum)	Whole cell sonicate
Babesia microti (I. ricinus, I. scapularis, blood transfusions, perinatal)	IRA, p32, p41, WCS
Babesia duncani (I. ricinus, I. scapularis, blood transfusions, perinatal)	Whole cell sonicate
Bartonella henselae	17kDa, 26kDa, SucB
Bartonella elizabethae	Whole cell sonicate
Bartonella vinsonii	Whole cell sonicate
Bartonella quintana	Whole cell sonicate
Anaplasma phagocytophilum (I. scapularis, I. ricinus)	MSP5, MSP2, OmpA
Ehrlichia chaffeensis (Amblyomma americanum)	Whole cell sonicate
Rickettsia typhi (Flea Xenopsylla cheopis, Ctenocephalides felis)	Omp B, surface antigen
Powassan virus (Hemaphysalis longicornis, I. scapularis, I.cookei)	Whole cell sonicate
Tick-borne encephalitis virus ( <i>I. ricinus, I. persulcatus</i> )	Whole cell sonicate
West Nile virus (I. ricinus, O. moubata)	Whole cell sonicate
Coxsackie virus (Amblyomma americanum)	Whole cell sonicate
Cytomegalovirus	EIA, gB,p150,p28,p52,pp65,p38
Epstein Barr virus	EA, EBNA1, VCA gp125,p18, p23
Parvovirus B19	VLP VLP2,VLP VP1/VP2 Co Capsid
Toxoplasma gondii (Multiple Ticks)	WCS, MIC3,p24,p29,p30

HSV-1	Whole cell sonicate
HSV-2	Whole cell sonicate
HHV-6	Whole cell sonicate

Table 2 consists of all the pathogens and their respective antigens.

## 616 **Table 3 Antigen sensitivities**

617

Pathogen	IgM		IgG		IgM+IgG		Gold Std [34- 48]	
	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
Borrelia burgdorferi	60	100	94	100	100	100	Early: 30-40 Late: 70-100	95-100
Babesia microti	79	98	91	97	99	96	70-80	94-100
Bartonella henselae	81	99	96	99	100	98	100	96.8
Anaplasma phagocytophilum	94	100	100	100	100	100	80-100	95-100
Ehrlichia chaffeensis	84	100	100	99	100	99	83	100
Rickettsia typhi	86	100	83	100	97	100	80-100	91-100
Powassan virus	100	100	100	100	100	100	89	35-84
Tickborne encephalitis	78	99	92	99	93	98	94-100	>95
West Nile virus	25	100	80	100	85	100	80-95	94-100
Coxsackie virus	56	100	100	100	100	100	94-97	100
Cytomegalovirus	100	100	100	100	100	100	89.2	95
Epstein Barr virus VCA	100	100	96	100	97	100	80-95	>95
Epstein Barr virus EBNA1	95	100	96	100	97	100	80-95	>95

Parvovirus B19	90	99	98	98	99	97	>90	>90
Toxoplasma gondii	100	99	100	100	100	99	>90	>95
HSV-1	100	100	98	100	98	100	97-100	98
HSV-2	100	100	98	100	98	100	97-100	98
HHV-6	95	100	95	100	95	100	>95	>95

Table 3 shows the IgG, IgM, and IgG+IgM sensitivities and specificities obtained using the Vibrant microarray and a comparison with the sensitivities and specificities of the current gold standard for respective pathogens.

621

#### 622 Table 4 Individual antigen sensitivities (B. burgdorferi)

Antigen 🗾	igM 🗾	lgG 🗾
VIsE1	61%	91%
С6	39%	60%
B31	37%	48%
B297	36%	57%
p18	6%	41%
p23	47%	68%
p28	4%	28%
p30	5%	35%
p31	17%	38%
p34	16%	41%
p39	29%	66%
p41	34%	53%
p45	5%	35%
p58	5%	35%
p66	7%	39%
p93	32%	60%

623

Table 4 shows the IgG and IgM values for the individual antigens of *Borrelia burgdorferi* 



Figure 1: Wafer Processing, Antigen Immobilisation, Pillar Plate Assembly. A poly (lactic acid) and poly (L-lysine) copolymer solution is coated onto the silicon wafers and further immobilized with protein probes [steps 1-3]. The wafers are then diced into microchips using a stealth dicing process [step 4]. A standard die sorting system is used to pick and place the microchips onto carrier plates [step 5]. The carrier tapes are loaded onto a high throughput surface mount technology (SMT) component placement system and individual microchips are placed onto 24-pillar plates. Each pillar consists of 87 microchips [step 6].



Figure 2: Overview of all the pathogens and their respective antigens used in the study.



Figure 3: Heat map showing Lyme disease antigen reactivity. The positivity cutoff for each antigen was set at greater than 10 chemiluminescent units (CU) (shown as yellow or red). The color key is as follows: Red - High positive (CU>20); Yellow, orange - Moderate positive (CU = 10.1-20); White - Negative (CU $\leq$ 10).